Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02667665
Other study ID # TRIAD1412
Secondary ID
Status Completed
Phase N/A
First received January 26, 2016
Last updated June 1, 2017
Start date February 19, 2016
Est. completion date November 15, 2016

Study information

Verified date June 2017
Source Translational Research Informatics Center, Kobe, Hyogo, Japan
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Examine the construct validity, the test-retest reliability, the concurrent validity with the standard dementia rating scales and the reactivity of a novel dementia rating scale "QuQu scale: QUick QUestion scale" final for the evaluation of patients with Alzheimer's Disease Dementia and Mild Cognitive Impairment.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date November 15, 2016
Est. primary completion date November 15, 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. Alzheimer's Disease Dementia and patients with cognitive concern without Dementia

2. Written Informed consent by each subject and/or a legal representative, and study informant. If the doctor decides that the patient has no trouble in understanding this study, the written informed consent of a legal representative may be exempted. If not, this study needs a written informed consent by a legal representative and the patient except the case where the consent is hardly obtained due to the progression of the disease.

Exclusion Criteria:

1. patients with other types of dementia (e.g. vascular dementia, Levy body dementia, frontotemporal dementia)

2. patients with other diseases which cause secondary dementia prior to Alzheimer's Disease Dementia

3. patients with other severe neurological disease or psychiatric disorder without Alzheimer's Disease Dementia

4. patients with other medical conditions where the investigators determine that it is inappropriate for the subject of this study (e.g. inappropriate for the evaluation of dementia rating scale)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Japan Kagawa University School of Medicine Kitagun Kagawa Prefecture

Sponsors (2)

Lead Sponsor Collaborator
Translational Research Informatics Center, Kobe, Hyogo, Japan Daiichi Sankyo Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary QuQu scale candidate 12 weeks
Primary Mini-Mental State Examination (MMSE) 12 weeks
Primary NPI-Caregiver Distress. Scale(NPI-D) 12 weeks
Primary Disability Assessment for Dementia (DAD) 12 weeks
Primary Clinical Dementia Rating 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05644977 - A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease Phase 1
Recruiting NCT05399888 - A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age Phase 2